Mesenchymal stem cell applications in polycystic ovary syndrome treatment
Journal of Experimental and Clinical Medicine (Turkey), cilt.38, sa.3, ss.361-366, 2021 (Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 38 Sayı: 3
- Basım Tarihi: 2021
- Doi Numarası: 10.52142/omujecm.38.3.29
- Dergi Adı: Journal of Experimental and Clinical Medicine (Turkey)
- Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, EMBASE
- Sayfa Sayıları: ss.361-366
- Anahtar Kelimeler: AMSC, BM-MSC, HUC-MSC, PCOS
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- İstanbul Medipol Üniversitesi Adresli: Evet
Özet
Mesenchymal stem cells (MSCs) are highly capable of self-renewal and differentiation. They can be isolated from a variety of sources such as adipose tissue, bone marrow, umbilical cord, tooth pulp and can be cultured under in vitro conditions. MSCs have anti-inflammatory, anti-apoptotic, angiogenic, immunomodulatory and many more therapeutic effects because of paracrine factors they secrete. Today, mesenchymal stem cells are used for treatment in more than twenty diseases, from spinal cord injuries to diabetes. However, there is little mention in the literature of the use of these cells in female reproductive system diseases. In this review, a limited number of clinical and experimental studies on the use of mesenchymal stem cells in the treatment of polycystic ovary syndrome, which is quite common in women, were examined and analyzed.